Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.40 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752557 | 0.81 | TSHR (0.44) | PGRCLK4CYP19A1 | |
| SCHEMBL25159882 | 0.80 | CYP11B2 (0.60) | LMNACYP17A1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL14884178 | 0.80 | MAPT (0.58) | LMNAMAPTCYP17A1CYP21A2CYP11B1 | |
| SCHEMBL17880388 | 0.80 | MAPT (0.58) | LMNAMAPTCYP17A1CYP21A2CYP11B1 | |
| SCHEMBL19062532 | 0.78 | TTR (0.44) | PGRGRM5CLK4MAOAMAOB | |
| SCHEMBL22534520 | 0.76 | ABCG2 (0.41) | MAPTPKN1PKN2CYP11B2CYP3A4 | |
| SCHEMBL4201635 | 0.75 | CYP2A6 (0.49) | PGRMAOAMAOBCYP3A4CYP2C9 | |
| SCHEMBL25544463 | 0.75 | MAPT (0.44) | CCNCCDK8LMNAMAPTPKN1 | |
| SCHEMBL25543833 | 0.75 | MAPT (0.44) | CCNCCDK8LMNAMAPTPKN1 | |
| SCHEMBL22799216 | 0.74 | MMP3 (0.52) | PGRCYP11B2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2023061263-A1 | SHP2 INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 北京泰德制药股份有限公司 | 2023-04-20 | — | — | WO | disclosed |
| CN-115484948-A | Compound and use thereof | 福宏治疗公司 | 2022-12-16 | — | — | CN | disclosed |
| EP-1858857-B1 | AZABICYCLOALKANE DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | LILLY CO ELI (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-1858857-B1 | AZABICYCLOALKANE DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | LILLY CO ELI (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20080261999-A1 | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-23 | — | — | US | disclosed |
| US-20080261999-A1 | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-23 | — | — | US | disclosed |
| US-20080261999-A1 | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CCNC 3907/4885CDK8 1753/4885PGR 2087/4885 |
| US-20080261999-A1 | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists | CHRNA1, CHRNA7, CHRNB1 | CCNC 3653/4885CDK8 2377/4885PGR 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.